New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
04:55 EDTSNE, SNE, SNE, SNE, SNE, SCMP, SCMP, SCMP, SCMP, SCMP, PRGO, PRGO, PRGO, PRGO, PRGO, OMER, OMER, OMER, OMER, OMER, NBY, NBY, NBY, NBY, NBY, LMNS, LMNS, LMNS, LMNS, LMNS, HALO, HALO, HALO, HALO, HALO, CAJ, CAJ, CAJ, CAJ, CAJ, AKRX, AKRX, AKRX, AKRX, AKRX, AGN, AGN, AGN, AGN, AGN, ACL, ACL, ACL, ACL, ACL, ABT, ABT, ABT, ABT, ABTAmerican Society of Cataract and Refractive Surgery to hold a symposium
2014 ASCRS-SOA Symposium & Congress is being held in Boston, MA on April 25-29.
News For ABT;ACL;AGN;AKRX;CAJ;HALO;LMNS;NBY;OMER;PRGO;SCMP;SNE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 8, 2014
16:10 EDTAGNAllergan initiated with a Buy at Deutsche Bank
Subscribe for More Information
09:34 EDTCAJCanon downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
08:42 EDTAGNSalix shares should be bought on weakness, says Sterne Agee
After Reuters yesterday afternoon reported that Actavis (ACT) plans to make a new merger approach to Allergan (AGN), Sterne Agee believes that Salix's standalone value is $162. The firm expects the shares to reach that level following approval of its Xifaxan IBS-D drug after the February 2015 PDUFA date.
07:19 EDTAGNCBI to hold a conference
Subscribe for More Information
06:23 EDTAGNActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
06:13 EDTSNENon-Apple notebook, tablet demand to be weak till 2Q15, DigiTimes reports
Demand for non-Apple (AAPL) notebooks and tablets may remain weak until the second quarter of 2015, reports DigiTimes. Citing Taiwan makers, the pressure due to booming sales from Apple products may decrease sales until Microsoft (MSFT) launches Windows 10 next year. Demand for Samsung (SSNLF), Sony (SNE) , And HTC smartphones have also dropped worldwide recently. Reference Link
October 7, 2014
18:29 EDTAGNOn The Fly: After Hours Movers
Subscribe for More Information
18:05 EDTAGNValeant, Pershing Square plan to raise Allergan bid by $15 a share, WSJ says
Subscribe for More Information
17:52 EDTAGNAllergan up 2.8% after Dow Jones says Valeant planning to boost bid for company
17:49 EDTAGNValeant up 3.9% after Dow Jones says planning to boost Allergan bid
Subscribe for More Information
17:47 EDTAGNValeant, Pershing Square planning to boost Allergan bid by $15 a share, DJ says
Subscribe for More Information
15:21 EDTAGNAllergan warms to sale as Actavis plans new approach, Reuters says
Subscribe for More Information
15:01 EDTAGNAllergan up 1.5% following report on Actavis planned approach on merger
14:59 EDTAGNActavis plans new approach to Allergan, Reuters reports
Subscribe for More Information
08:34 EDTHALOHalozyme issued patent for diagnosing hyaluronan-associated diseases
Subscribe for More Information
08:04 EDTSNEAVG Technologies, Sony Mobile announce mobile security partnership
Subscribe for More Information
07:48 EDTAGNSalix reinstated with a Buy at Jefferies
Subscribe for More Information
07:12 EDTAGNAllergan requests Ackman be hindered from voting at meeting, Bloomberg says
In an effort to avoid an unsolicited $54B acquisition offer from Valeant Pharmaceuticals (VRX), Allergan (AGN) filed a request in a California court for a judge to hinder Bill Ackmanís Pershing Square from voting its 10% stake at the December shareholder meeting, according to Bloomberg, citing the filing. A hearing regarding Allergan's request is set to occur on October 28. Reference Link
07:06 EDTOMEROmeros, Hospira enter into commercial suply agreement for Omidria
Omeros Corporation (OMER) said in a filing that on October 3, it, Hospira S.p.A. and Hospira Worldwide, Inc. (HSP) entered into a Commercial Supply Agreement, pursuant to which Hospira will act as a non-exclusive supplier of Omerosí product Omidria for commercial sale in the United States and the European Union. Pursuant to the Supply Agreement, Hospira has agreed to manufacture and supply, and Omeros has agreed to purchase, a minimum percentage of Omerosí requirements of Omidria for commercial sales and clinical supplies for the development of additional therapeutic indications in the United States. In addition, upon receipt of marketing approval in the EU, Hospira has agreed to manufacture and supply a portion of Omerosí requirements of Omidria in the EU in an amount to be mutually agreed by the parties within four months of marketing approval in Europe, with there being no minimum purchase and supply requirement in the EU if the parties do not reach agreement during such time period and the agreement is not amended thereafter. The Supply Agreement obligates Omeros to provide to Hospira a rolling, non-binding long-term forecast of Omerosí estimated required quantities of Omidria. The Supply Agreement has an initial term of five years from the date of first commercial sale of Omidria in any country in the Territory. Upon termination of the Supply Agreement, except in the case of termination for an uncured breach by Hospira, Omeros will be required to purchase all of Hospiraís inventory of Omidria and, if applicable, work in progress and reimburse Hospira for all supplies purchased or ordered based on firm purchase orders or Omerosí estimates of its requirements of Omidria.
06:41 EDTSNESony's internet TV service could cost up to $80 per month, NY Post reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use